Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children.

The Journal of allergy and clinical immunology - 1 Dec 2016

Frémond Marie-Louise, Rodero Mathieu Paul, Jeremiah Nadia, Belot Alexandre, Jeziorski Eric, Duffy Darragh, Bessis Didier, Cros Guilhem, Rice Gillian I, Charbit Bruno, Hulin Anne, Khoudour Nihel, Caballero Consuelo Modesto, Bodemer Christine, Fabre Monique, Berteloot Laureline, Le Bourgeois Muriel, Reix Philippe, Walzer Thierry, Moshous Despina, Blanche Stéphane, Fischer Alain, Bader-Meunier Brigitte, Rieux-Laucat Fréderic, Crow Yanick Joseph, Neven Bénédicte

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child, Preschool
Share to Janus Kinase 1

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Membrane Proteins

Share to Nitriles

Share to Protein Kinase Inhibitors

Share to Pyrazoles

Share to Pyrimidines

Source

Identifiers

PMID: 27554814
DOI: 10.1016/j.jaci.2016.07.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children.PMID 27554814Read ↗

Tofacitinib relieves symptoms of stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173.Semantic proximity Read ↗

TMEM173 variants and potential importance to human biology and disease.Semantic proximity Read ↗

Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2.Semantic proximity Read ↗

First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta-analysis.Semantic proximity Read ↗

Three children with Milroy disease and de novo mutations in VEGFR3.Semantic proximity Read ↗

Ruxolitinib in a Child With JAK2 Exon 12 Mutant Polycythemia Vera.Semantic proximity Read ↗

Therapeutic targeting of Janus kinases.Semantic proximity Read ↗

Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation.Semantic proximity Read ↗

Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis.Semantic proximity Read ↗

Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia.Semantic proximity Read ↗

Ruxolitinib reverses systemic vasculitis driven by JAK2 V617F-mutated essential thrombocythemia: a case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.